Last update 08 May 2025
Pierre Fabre (Shanghai) Medical Technology Co., Ltd.

Pierre Fabre (Shanghai) Medical Technology Co., Ltd.

Private Company|2011|Shanghai Shi, China

Overview

Tags

Congenital Disorders
Nervous System Diseases
Immune System Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms1
Immune System Diseases1
Endocrinology and Metabolic Disease1
Hemic and Lymphatic Diseases1
Nervous System Diseases1
Top 5 Drug TypeCount
Small molecule drug1
Top 5 TargetCount
MEK1 x MEK21

Related

1
Drugs associated with Pierre Fabre (Shanghai) Medical Technology Co., Ltd.
Binimetinib
Target
MEK1 x MEK2
Mechanism
MEK1 inhibitors [+1]
Active Org.
Pierre Fabre Médicament SAS [+11]
Originator Org.
Array BioPharma, Inc.Array BioPharma, Inc.
Active Indication
BRAF mutated anaplastic thyroid cancer [+31]
Inactive Indication
Acute Myeloid Leukemia [+36]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date27 Jun 2018
100 Clinical Results associated with Pierre Fabre (Shanghai) Medical Technology Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Pierre Fabre (Shanghai) Medical Technology Co., Ltd.
Login to view more data
100 Deals associated with Pierre Fabre (Shanghai) Medical Technology Co., Ltd.
Login to view more data
100 Translational Medicine associated with Pierre Fabre (Shanghai) Medical Technology Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 29 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
NDA/BLA
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Binimetinib
 ( MEK1 x MEK2 )		BRAF V600E mutant Non-small Cell Lung Cancer
More
NDA/BLA
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free